Cite
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
MLA
Huang, Yen-Hsiang, et al. “The Impact of Different First-Line EGFR-TKIs on the Clinical Outcome of Sequential Osimertinib Treatment in Advanced NSCLC with Secondary T790M.” Scientific Reports, vol. 11, no. 1, June 2021, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41598-021-91657-7.
APA
Huang, Y.-H., Tseng, J.-S., Hsu, K.-H., Chen, K.-C., Su, K.-Y., Yu, S.-L., Chen, J. J. W., Yang, T.-Y., & Chang, G.-C. (2021). The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Scientific Reports, 11(1), 1–10. https://doi.org/10.1038/s41598-021-91657-7
Chicago
Huang, Yen-Hsiang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, and Gee-Chen Chang. 2021. “The Impact of Different First-Line EGFR-TKIs on the Clinical Outcome of Sequential Osimertinib Treatment in Advanced NSCLC with Secondary T790M.” Scientific Reports 11 (1): 1–10. doi:10.1038/s41598-021-91657-7.